

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: John Nicholas STANIFORTH, et al.

Serial No.: 10/552,231

Filed: April 21, 2006

For: **PHARMACEUTICAL COMPOSITIONS  
COMPRISING APOMORPHINE FOR  
PULMONARY INHALATION**

TC/A.U.: 1627

Examiner: Samira JEAN-LOUIS

Confirmation No.: 8836

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 8, 2010

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. §§ 1.56 and 1.97, Applicant hereby submits this Supplemental Information Disclosure Statement, including one (1) sheet of Form PTO-1449, for consideration by the Examiner in connection with the above-identified patent application.

Applicants respectfully request that the references cited in the accompanying PTO 1449 form be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing date of a First Office Action. Therefore, no fee is believed due. In the event any fee is due in connection with this submission the Commissioner for Patents is hereby authorized to charge such fee to Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: Leslye B. Davidson  
Leslye B. Davidson, Reg. No. 38,854

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, NY 10018  
(212) 736-1940